Ventura and colleagues proposed that pharmacological inhibition of FASN with TVB-3166 reduces cell proliferation and xenograft tumor growth of KRAS mutated NSCLC, but not CRC cell lines via, at least in part, inhibition of the PI3K–AKT–mTOR pathway [12]. Here, KRAS is linked to neoplasm.